Sarepta Therapeutics' (SRPT) "Neutral" Rating Reiterated at Mizuho

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at Mizuho in a research report issued on Monday, MarketBeat.com reports. They presently have a $14.00 price target on the biotechnology company's stock. Mizuho's price target suggests a potential upside of 3.33% from the stock's previous close.

SRPT has been the subject of a number of other reports. Morgan Stanley reissued an "equal weight" rating and set a $40.00 price objective (down from $113.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. The Goldman Sachs Group cut Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating and set a $29.00 price objective for the company. in a research report on Tuesday, June 17th. Cantor Fitzgerald reissued a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Royal Bank Of Canada cut their price target on Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a report on Thursday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Sarepta Therapeutics from $28.00 to $20.00 and set an "overweight" rating for the company in a research note on Monday. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of "Hold" and a consensus target price of $53.50.

Sarepta Therapeutics Stock Performance

SRPT traded down $0.53 on Monday, reaching $13.55. The stock had a trading volume of 11,927,753 shares, compared to its average volume of 2,745,048. The business's 50-day moving average price is $28.42 and its two-hundred day moving average price is $67.58. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a 12-month low of $11.95 and a 12-month high of $150.48. The company has a market cap of $1.33 billion, a P/E ratio of -4.99 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same period last year, the firm posted $0.73 EPS. The business's quarterly revenue was up 80.2% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the business. Generali Investments CEE investicni spolecnost a.s. raised its stake in shares of Sarepta Therapeutics by 5,166.3% during the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 105,326 shares of the biotechnology company's stock valued at $1,801,000 after purchasing an additional 103,326 shares during the period. Janney Montgomery Scott LLC lifted its position in Sarepta Therapeutics by 123.5% in the second quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company's stock valued at $492,000 after purchasing an additional 15,882 shares during the last quarter. Tempus Wealth Planning LLC grew its holdings in Sarepta Therapeutics by 475.8% in the 2nd quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company's stock worth $353,000 after acquiring an additional 17,070 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in Sarepta Therapeutics by 2.2% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company's stock valued at $492,000 after purchasing an additional 607 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Sarepta Therapeutics by 21.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock valued at $14,842,000 after purchasing an additional 155,358 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.